Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach

European Journal of Medicinal Chemistry

Volumn 59, Issue , 2013, Pages 141-149

  Zhang, Zhichao ^a   Song, Ting ^a,b   Li, Xiangqian ^a   Wu, Zhiyong ^a   Feng, Yingang ^c   Xie, Feibo ^a   Liu, Chengwu ^a   Qin, Jianquan ^a   Chen, Hongbo ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^b PEKING UNIVERSITY   (China)

^c QINGDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY   (China)

Author keywords

Anticancer; Fragment based approach; Mcl 1; Small molecule inhibitor

Indexed keywords

(BENZYLAMINOCARBONYL) 3 STYRYLACRYLONITRILE; 2 (2 OXO 2H 6 (4 CHLOROPHENOXY)ACENAPHTHYLEN 1 YLIDENE)MALONONITRILE; 2 (2 OXO 2H 6 (4 ISOPROPYLPHENOXY)ACENAPHTHYLEN 1 YLIDENE)MALONONITRILE; 2 (2 OXO 2H 6 (4 METHOXYPHENOXY)ACENAPHTHYLEN 1 YLIDENE)MALONONITRILE; 2 (2 OXO 2H 6 (4 TERT AMYLPHENOXY)ACENAPHTHYLEN 1 YLIDENE)MALONONITRILE; 2 CYANO 3 PHENYL 2 PROPENAMIDE; 2 CYANO 5 PHENYL 2,4 PENTADIENAMIDE; ACETAMIDE DERIVATIVE; ACRYLONITRILE; MALONONITRILE; MYELOID CELL LEUKEMIA SEQUENCE 1 INHIBITOR; N BENZYL 2 CYANOACETAMIDE; N ETHYL 2 CYANOACETAMIDE; N N PROPYL 2 CYANOACETAMIDE; PROTEIN INHIBITOR; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SOLUBILITY; HYDROGEN BOND; ISOTHERMAL TITRATION CALORIMETRY; NUCLEAR MAGNETIC RESONANCE; PREDICTION;

ACRYLONITRILE; BENZYLAMINES; BINDING SITES; BIOMIMETICS; BLOTTING, WESTERN; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 84870342233     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.050     Document Type: Article

References (33)

1. M.R. Arkin, and J.A. Wells Small-molecule inhibitors of protein-protein interactions progressing towards the dream Nat. Rev. Drug Discov. 3 2004 301 308
2. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009
3. S. Cory, D.C. Huang, and J.M. Adams The Bcl-2 family: roles in cell survival and oncogenesis Oncogene 22 2003 8590 8607
4. M.F.V. Delft, A.H. Wei, K.D. Mason, C.J. Vandenberg, L. Chen, P.E. Czabotar, S.N. Willis, C.L. Scott, C.L. Day, S. Cory, J.M. Adams, A.W. Roberts, and D.C.S. Huang The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 10 2006 389 399
5. M.R. Warr, and G.C. Shore Unique biology of Mcl-1: therapeutic opportunities in cancer Curr. Mol. Med. 8 2008 138 147
6. A.S. Azmi, and R.M. Mohammad Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy J. Cell. Physiol. 218 2009 13 21
7. Z. Zhang, L. Jin, X. Qian, M. Wei, Y. Wang, J. Wang, Y. Yang, Q. Xu, Y. Xu, and F. Liu Novel Bcl-2 inhibitors: discovery and mechanism study of small organic apoptosis-inducing agents ChemBioChem 8 2007 113 121
8. Z. Zhang, T. Song, T. Zhang, G. Wu, J. Gao, L. An, and G. Du A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1 Int. J. Cancer 128 2010 1724 1735
9. Z. Zhang, G. Wu, F. Xie, T. Song, and X. Chang 3-Thiomorpholin-8-oxo-8H- acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1):structure-based design and structure-activity relationship studies J. Med. Chem. 54 2011 1101 1105
10. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
11. D.F. Veber, S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
12. M.C. Wenlock, R.P. Austin, P. Barton, A.M. Davis, and P.D.A. Leeson Comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
13. C.A. Lipinski Lead- and drug-like compounds: the rule-of-five revolution Drug Discov. Today Technol. 1 2004 337 341
14. G. Chessari, and A.J. Woodhead From fragment to clinical candidate-a historical perspective Nat. Rev. Drug Discov. 14 2009 668 675
15. D.C. Rees, M. Congreve, C.W. Murray, and R. Carr Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672
16. P.J. Hajduk, and J.A. Greer Decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 6 2007 211 219
17. M. Congreve, G. Chessari, D. Tisi, and A.J. Woodhead Recent developments in fragment-based drug discovery J. Med. Chem. 51 2008 3661 3680
18. P.J. Hajduk Fragment-based drug design: how big is too big? J. Med. Chem. 49 2006 6972 6976
19. I.D. Kuntz, K. Chen, K.A. Sharp, and P.A. Kollman The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002
20. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431
21. S. Schultes, C. de Graaf, E.E.J. Haaksma, I.J.P. de Esch, R. Leurs, and O. Kramer Ligand efficiency as a guide in fragment hit selection and optimization Drug Discov. Today 7 2010 157 162
22. D. Tanaka, Y. Tsuda, J. Albert, T. Shiyama, T. Nishimura, N. Chiyo, Y. Tominaga, N. Sawada, T. Mimoto, and N. Kusunose A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors J. Med. Chem. 54 2011 851 857
23. G.E. Kloe, D. Bailey, R. Leurs, and I.J.P. de Esch Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 14 2009 630 646
24. A. Ciulli, G. Williams, A.G. Smith, T.L. Blundell, and C. Abell Probing hot spots at protein ligand binding sites: a fragment-based approach using biophysical methods J. Med. Chem. 49 2006 4992 5000
25. M. Congreve, R. Carr, C. Murray, and H. Jhoti A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
26. P.E. Czabotar, E.F. Lee, M.F. van Delft, C.L. Day, B.J. Smith, D.C. Huang, W.D. Fairlie, M.G. Hinds, and P.M. Colman Structural insights into the degradation of Mcl-1 induced by BH3 domains Proc. Natl. Acad. Sci. U. S. A. 104 2007 6217 6222
27. E.F. Lee, P.E. Czabotar, M.F. Delft, E.M. Michalak, M.J. Boyle, and S.N. Willis A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation J. Cell Biol. 180 2008 341 355
28. C.W. Murray, and M.L. Verdonk The consequences of translational and rotational entropy lost by small molecules on binding to proteins J. Comput. Aided Mol. Des. 16 2002 741 753
29. G. Saxty, S.J. Woodhead, V. Berdini, T.G. Davies, M.L. Verdonk, P.G. Wyatt, and R.G. Boyle Identification of inhibitors of protein kinase B using fragment-based lead discovery J. Med. Chem. 50 2007 2293 2296
30. G. Tang, Z. Nikolovska-Coleska, S. Qiu, C. Yang, J. Guo, and S. Wang Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins J. Med. Chem. 51 2008 717 720
31. G. Tang, K. Ding, Z. Nikolovska-Coleska, C. Yang, and S. Qiu Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins J. Med. Chem. 50 2007 3163 3166
32. A. Li, and S.H. Yalkowsky Solubility of organic solutes in ethanol/water mixtures J. Pharm. Sci. 83 1994 1735 1740
33. A. Jouyban, and J.W.E. Acree In silico prediction of drug solubility in water-ethanol mixtures using Jouyban-Acree model J. Pharm. Pharm. Sci. 9 2006 262 269